BASELINE CLINICAL AND PET‐CT TUMOR BURDEN PARAMETERS DO NOT PREDICT OUTCOME OF RELAPSE/REFRACTORY AGGRESSIVE B CELL LYMPHOMA PATIENTS TREATED WITH ANTI‐CD19 CAR T‐CELLS. (12th June 2019) - Avigdor, A.